In contrast, another approach for driving de novo resistance was the knockdown of 53BP1 in BRCA1-mutant ovarian cancer cells, namely the UWB1.289 cell derivatives UWB1.289/53BP1−/− cells. Here, BRCA1 is linked to ovarian carcinoma.